In regards to the delay in TNBC first injection, I
Post# of 148292
(Total Views: 299)
Posted On: 04/04/2019 12:53:34 PM
In regards to the delay in TNBC first injection, I’m not concerned. The mice model results are very promising and we already know that leronlimab has a low side effect profile. And as far as the company has said, only the HIV indication is up for licensing discussions, not TNBC or any other cancer indications. CYDY may be waiting to perfect measuring CCR5 receptors in patients so that dosing is more accurate. If they do this, TNBC patients are likely to have a better response.
The addition of RP and his cancer knowledge and prostate test changed the game for CYDY. Unfortunately nothing moves quickly in the biotech and FDA world so monitoring the stock day to day is often futile.
The addition of RP and his cancer knowledge and prostate test changed the game for CYDY. Unfortunately nothing moves quickly in the biotech and FDA world so monitoring the stock day to day is often futile.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼